• In May 2026, Boston Scientific voluntarily began recalling multiple CRE and CRE Pro Wireguided endoscopy devices worldwide, after identifying potential sterile breaches in the packaging of tens of thousands of Class II–classified units, with the US FDA now listing the recalls as ongoing.
• The concentration of recalls across several size ranges of the same product family highlights how a single packaging issue can ripple through Boston Scientific’s global supply chain, regulatory workload, and hospital relationships at the same time.
• We’ll now examine how this large-scale, packaging-related sterilization concern may affect Boston Scientific’s previously outlined growth, margin, and risk narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Boston Scientific Investment Narrative Recap

To own Boston Scientific, you need to believe its diversified device portfolio and history of product innovation can offset pricing, reimbursement, and integration pressures. The recent global recalls of CRE and CRE Pro endoscopy devices raise operational and reputational questions, but at this stage they appear more like a quality and supply chain setback than a clear-hit to the core near term growth driver, which is still tied to higher value cardiac and electrophysiology procedures, and to margin discipline amid cost headwinds.

In that context, the US$4 billion increase in share repurchase authorization in February 2026 stands out. It signaled management’s confidence in cash generation and balance sheet strength before this series of recalls surfaced. For investors, the contrast between returning capital at scale and managing multiple, globally distributed device issues sharpens the focus on whether Boston Scientific can keep funding buybacks, clinical programs, and integration efforts without letting quality and regulatory risks creep higher.

Yet against this backdrop, the risk that repeated product quality issues could erode trust with regulators and hospital buyers is something investors should be aware of...

Boston Scientific's narrative projects $25.8 billion revenue and $4.8 billion earnings by 2029.

Uncover how Boston Scientific's forecasts yield a $75.00 fair value, a 70% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were assuming revenue could reach about US$28.0 billion and earnings US$5.5 billion by 2029, but the scale of these packaging related recalls may force you to reassess how realistic that faster growth and smoother acquisition integration story really looks compared with the more cautious baseline narrative.

Explore 8 other fair value estimates on Boston Scientific - why the stock might be worth just $69.00!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Boston Scientific research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Boston Scientific research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Boston Scientific's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.